Sylatron
Drug - Sylatron (peginterferon alfa-2b) [Merck]
November 2011
Therapeutic Area - Oncology
Approval criteria
- Patient has melanoma with microscopic or gross nodal involvement AND
- Patient had definitive surgical resection or complete lymphadenectomy within last 84 days
Exclusion criteria
- Patient history of anaphylaxis to peginterferon alfa-2b or interferon alfa-2b OR
- autoimmune hepatitis OR
- hepatic decompensation (Child-Pugh score >6 [class B and C])
Background information
SYLATRON is an alpha interferon indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy.
Questions?
MHCP Provider Call Center 651-431-2700 or 800-366-5411